Author: ["Arthur A. Vandenbark","Yuan K. Chou","Ruth Whitham","Michele Mass","Abigail Buenafe","Diane Liefeld","Daniel Kavanagh","Shelley Cooper","George A. Hashim","Halina Offner","Dennis N. Bourdette"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
A T–cell receptor (TCR) peptide vaccine from the Vβ5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)–specific T cells boosted peptide–reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide–specific T helper 2 cells directly inhibited MBP–specific T helper 1 cells in vitro through the release of interleukin–10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.Cite this article
Vandenbark, A., Chou, Y., Whitham, R. et al. Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial. Nat Med 2, 1109–1115 (1996). https://doi.org/10.1038/nm1096-1109 